C. R. Bard reports a lower fourth-quarter profit, due largely to hefty gains recorded for a patent infringement suit against W.L. Gore & Associates and the sale of its electrophysiology unit in 2013.
A tough comparison with the year-ago quarter pushed C.R. Bard's (NYSE:BCR) 4th-quarter profits down 80%, due largely to hefty gains from patent infringement suit and the 2013 sale of its electrophysiology unit.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1BYFOAV
Cap comentari:
Publica un comentari a l'entrada